Metoclopramide

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S2404
R5281		 Ashkenazi-Hoffnung, 2013 Hypospadias at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 3.11 [0.12;79.65] C 1/29   0/29 1 29
ref
S4906
R12955		 Lind, 2013 Isolated Second- or Third-Degree Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: Yes 1.00 [0.50;2.30] 10/31   1,527/5,820 1,537 31
ref
S2397
R2995		 Pasternak, 2013 Hypospadias 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.84 [0.63;1.12] 58/13,201   302/50,704 360 13,201
ref
S2749
R3652		 Anderka, 2012 Hypospadias 1st trimester case control unexposed, sick Adjustment: Yes 1.17 [0.39;3.55] 6/15   649/2,596 655 15
ref
Total 4 studies 0.88 [0.68;1.14] 2,553 13,276
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Ashkenazi-Hoffnung, 2013Ashkenazi-Hoffnung, 2013 3.11[0.12; 79.65]1291%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Lind, 2013Lind, 2013 1.00[0.50; 2.30]1,5373112%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Pasternak, 2013Pasternak, 2013 0.84[0.63; 1.12]36013,20182%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Anderka, 2012Anderka, 2012 1.17[0.39; 3.55]655156%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 0% 0.88[0.68; 1.14]2,55313,2760.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.85[0.64; 1.13]36113,2300%NAAshkenazi-Hoffnung, 2013 Pasternak, 2013 2 case control studiescase control studies 1.05[0.56; 1.97]2,192460%NALind, 2013 Anderka, 2012 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.86[0.66; 1.12]1,89713,2320%NALind, 2013 Pasternak, 2013 2 unexposed, sickunexposed, sick 1.17[0.39; 3.53]65515 -NAAnderka, 2012 1 exposed to other treatment, sickexposed to other treatment, sick 3.11[0.12; 79.65]129 -NAAshkenazi-Hoffnung, 2013 1 Tags Adjustment   - No  - No 3.11[0.12; 79.65]129 -NAAshkenazi-Hoffnung, 2013 1   - Yes  - Yes 0.87[0.67; 1.13]2,55213,2470%NALind, 2013 Pasternak, 2013 Anderka, 2012 3 All studiesAll studies 0.88[0.68; 1.14]2,55313,2760%NAAshkenazi-Hoffnung, 2013 Lind, 2013 Pasternak, 2013 Anderka, 2012 40.210.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.93.81.9860.000Ashkenazi-Hoffnung, 2013Lind, 2013Pasternak, 2013Anderka, 2012

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.86[0.66; 1.12]1,89713,2320%NALind, 2013 Pasternak, 2013 2 unexposed, sick controlsunexposed, sick controls 1.17[0.39; 3.53]65515 -NAAnderka, 2012 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 3.11[0.12; 79.65]129 -NAAshkenazi-Hoffnung, 2013 10.510.01.0